Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
Sun Young Rha(Yonsei University), Xiaochun Zhang(Shanghai East Hospital), Juan Manuel O’Connor(Instituto Alexander Fleming), Jeeyun Lee(Samsung Medical Center), Zev A. Wainberg(University of California, Los Angeles), Sonal Bordia(Merck & Co., Inc., Rahway, NJ, USA (United States)), M. Fernández(University College London Hospitals NHS Foundation Trust), Kai‐Keen Shiu(University College London Hospitals NHS Foundation Trust), Weng Ng(Sir Run Run Shaw Hospital), Mauricio Mahave, Gustavo Vasconcelos Alves(Marqués de Valdecilla University Hospital), Gustavo R. Alves(Universidade do Porto), Guillermo Méndez(Sorbonne Université), Morteza Aghmesheh(New South Wales Department of Health), César Sánchez(Pontificia Universidad Católica de Chile), Shukui Qin(81th Hospital of PLA), Patricio Yañez(Universidad de La Frontera), Hongming Pan(Sir Run Run Shaw Hospital), Timuçin Çil(Sorbonne Université), Karina Vianna(Instituto Brasileiro de Controle do Câncer), Michael J. Raphael, Lucjan Wyrwicz(The Maria Sklodowska-Curie National Research Institute of Oncology), Maeve A. Lowery(Shanghai East Hospital), Do‐Youn Oh(Seoul National University Hospital), Jamil Asselah, Marcelo Garrido(Pontificia Universidad Católica de Chile), Raymond Woo-Jun Jang, Ann Tan, Fábio Franke(National Cancer Center), Scott Berry, Jin Li(Shanghai Cancer Institute), Min‐Hee Ryu(Ulsan College), Yuxian Bai(Harbin Medical University), Rachel Wong(Box Hill Hospital), Diego Kaen(National University of La Rioja), Mauricio Peressoni, Suxia Luo(Zhengzhou University), Lina Yin(University of California, Los Angeles), Alvaro Yanzi Castilla, Pamela Salman(Fundación Arturo López Pérez), Felipe Melo Cruz(Instituto Brasileiro de Controle do Câncer), Felipe Jose Cruz(Hospital Nossa Senhora da Conceição), Juan Cundom, Carlos Eduardo Mattos da Cunha Andrade, Fernando Rivera(Samsung Medical Center), Pooja Bhagia(Merck & Co., Inc., Rahway, NJ, USA (United States)), Maria Marcela Monteiro, Patricio Yañez Weber(Universidad de La Frontera)
Cited by 614
Related Papers
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Cetuximab for the Treatment of Colorectal Cancer
|New England Journal of Medicine|2007|1.8k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
|Science Translational Medicine|2016|1.5k